We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Avacta

FY21 results: a year of frustrations and opportunities

Update | 06 April 2022

Redx Pharma

RXC008 nominated as GI-ROCK drug candidate

Lighthouse | 30 March 2022

Futura Medical

Menarini to commercialise MED3000 in South Korea

Lighthouse | 23 March 2022

MaxCyte

Opening the next chapter

Outlook | 09 March 2022

HUTCHMED

A genuinely global R&D-driven biopharma business

Lighthouse | 03 March 2022

Allergy Therapeutics

Solid commercial performance with major R&D upside

Outlook | 03 March 2022

Nexstim

First steps on path towards longer-term profitability

Update | 02 March 2022

Redx Pharma

Building on an impressive track-record

Outlook | 17 February 2022

Redx Pharma

FY21 results: a year of continuing delivery

Update | 27 January 2022

Allergy Therapeutics

FDA green lights VLP Peanut vaccine Phase I trial

Lighthouse | 26 January 2022
< 6 7 8 9 10 11 12 13 14 15 >
397 results found.